Gossamer Bio Submits First FDA NDA, Cash Falls to $51.2M

Gossamer Bio, Inc. (Nasdaq: GOSS) said on 10 November 2026 that it submitted a New Drug Application to the U.S. Food and Drug Administration in September 2026 for seralutinib in pulmonary arterial hypertension, the company's first NDA filing. Cash, cash equivalents and marketable securities totaled $51.2 million at 30 September 2026, down from $57.0 million at 30 June 2026. Quarterly revenue from contracts with collaborators reached $38.4 million, and net loss was $48.1 million, or $7.36 per share.

Context — Why the NDA and the Cash Runway Both Matter Now

The filing is the first regulatory submission in Gossamer's history, and the company tied its near-term funding directly to it. Under a structured private placement announced in August 2026, an initial closing delivered roughly $25 million, with up to about $125 million more committed upon FDA acceptance of the seralutinib NDA in PAH, subject to that milestone occurring in 2026 and other customary closing conditions.

That conditionality is the central fact of the quarter. The company said FDA acceptance would, subject to other customary closing conditions, release up to approximately $125 million in additional committed capital to support its priorities, including launch preparations. Gossamer said it remains focused on supporting the agency's review and preparing for a potential commercial launch of seralutinib in 2027.

Cash fell by $5.8 million between 30 June and 30 September 2026. Working capital was negative $39.5 million at 30 September 2026, against positive $104.2 million at 31 December 2025. Total stockholders' deficit stood at $122.8 million, versus $122.8 million at the prior year end.

Gossamer reacquired worldwide development and commercial rights to seralutinib from Chiesi Farmaceutici S.p.A. in July 2026, terminating their prior collaboration. The agreement provided a one-time $5 million payment from Chiesi, with no upfront cash payment by Gossamer. Chiesi retains a capped royalty and certain regulatory and commercial milestone payments.

The company completed a 1-for-80 reverse stock split in September 2026, with split-adjusted trading continuing under the existing Nasdaq symbol GOSS. Gossamer said the split was effected to regain compliance with the Nasdaq minimum bid price requirement.

Data — What the Numbers Show

The NDA rests on the Phase 3 PROSERA Study as one adequate and well-controlled clinical investigation, together with confirmatory evidence from the Phase 2 TORREY Study and additional supportive analyses. Gossamer noted that seralutinib is investigational and has not been approved by any regulatory authority. The FDA will determine whether to accept the NDA for filing following its initial review.

Revenue from contracts with collaborators rose to $38.4 million for the quarter ended 30 September 2026 from $13.3 million in the same period of 2025. The company attributed the $25.1 million increase primarily to revenue recognized upon termination of the Chiesi Collaboration Agreement in July 2026.

Research and development expenses fell to $18.8 million from $45.5 million a year earlier. Gossamer said the change was primarily driven by a $15.7 million decrease in costs associated with seralutinib clinical trials. General and administrative expenses were $9.6 million, versus $9.4 million.

Metric	Q3 2026	Q3 2025
Revenue from collaborators	$38.4M	$13.3M
R&D expenses	$18.8M	$45.5M
G&A expenses	$9.6M	$9.4M
Net loss	$48.1M	$48.2M
Net loss per share	$7.36	$16.92

Net loss per share narrowed sharply despite a nearly flat net loss, because weighted average common shares outstanding, basic, rose to 6,530,004 from 2,849,768. Other expense included a $56.5 million remeasurement of warrant liability and a $5.6 million remeasurement of derivative liability. For the nine months ended 30 September 2026, net loss was $77.8 million, against $123.1 million a year earlier, and included a $43.8 million gain on debt extinguishment.

Analysis — What It Means for Gossamer and Biotech Financing

Gossamer's quarter shows how much of a clinical-stage biotech's balance sheet now depends on a single regulatory decision. The $25 million initial tranche is already drawn; the remaining committed capital is contingent on FDA acceptance, not approval, of the seralutinib NDA. That distinction matters for anyone tracking GOSS, because acceptance is an administrative milestone that arrives before any efficacy judgment.

The warrant structure adds a second layer. Warrants tied to FDA approval could provide up to approximately $100 million in additional gross proceeds, contingent on approval of seralutinib and cash exercise of the warrants. Together with the committed tranches, the placement carries total potential gross proceeds of up to approximately $250 million. None of the later stages is guaranteed.

The counter-argument is dilution. Weighted average shares roughly doubled year over year, and the reverse split lifted the reported loss per share from $16.92 to $7.36 without changing the underlying net loss. A 1-for-80 split also reduces share count mechanically, so per-share comparisons across the split date are not like-for-like. The company did not disclose the terms of the placement beyond the headline tranches.

Revenue quality deserves scrutiny. The $25.1 million year-over-year increase came from terminating the Chiesi collaboration, not from product sales. Gossamer has no approved product and no commercial revenue. The company did not disclose an FDA action date for the NDA.

Outlook — What to Watch Next

The next catalyst is FDA acceptance of the seralutinib NDA, which the company framed as a 2026 event and which gates the roughly $125 million second closing. Gossamer also pointed to a potential commercial launch of seralutinib in 2027, contingent on approval.

Investors tracking GOSS should watch whether the agency accepts the filing, whether the second closing conditions are satisfied, and whether warrant exercises follow any approval. The company's cash position of $51.2 million against a negative $39.5 million working capital balance sets the runway context for those decisions.

Gossamer did not disclose a PDUFA date, a review timeline, or the specific closing conditions attached to the second tranche. Any FDA action, or its absence, is the variable that determines whether the committed capital converts into cash.

Frequently Asked Questions

What does FDA acceptance of the seralutinib NDA actually mean?

Acceptance means the FDA has completed its initial review and decided the application is complete enough to file, not that the drug works or is approved. Gossamer said the agency will determine whether to accept the NDA following that initial review. Acceptance would, subject to other customary closing conditions, release up to approximately $125 million of committed capital under the August 2026 structured private placement.

Why did Gossamer's revenue jump to $38.4 million this quarter?

The increase was not commercial. Gossamer said the $25.1 million year-over-year rise was primarily attributable to revenue recognized upon termination of the Chiesi Collaboration Agreement in July 2026, when the company reacquired worldwide rights to seralutinib. Chiesi paid Gossamer a one-time $5 million and retains a capped royalty plus certain milestone payments.

How does the reverse stock split affect Gossamer's reported per-share figures?

Gossamer completed a 1-for-80 reverse split in September 2026 to regain compliance with the Nasdaq minimum bid price requirement. The split mechanically reduced the share count, so the reported net loss per share of $7.36 in Q3 2026 is not directly comparable to the $16.92 reported for Q3 2025 on the pre-split share base. Net loss was nearly unchanged at $48.1 million versus $48.2 million.

Bottom Line

Gossamer's first FDA filing is in, but roughly $125 million of committed capital still hinges on the agency accepting it in 2026.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.